These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 8038902)
1. Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog). Lee EJ; Kim KR; Lim SK; Lee HC; Kim DI; Kim SH; Huh KB Eur J Endocrinol; 1994 Jul; 131(1):109-12. PubMed ID: 8038902 [TBL] [Abstract][Full Text] [Related]
2. Reduction in size of a thyrotropin- and gonadotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog). Sy RA; Bernstein R; Chynn KY; Kourides IA J Clin Endocrinol Metab; 1992 Mar; 74(3):690-4. PubMed ID: 1740506 [TBL] [Abstract][Full Text] [Related]
3. Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201-995). Warnet A; Lajeunie E; Gelbert F; Duet M; Chanson P; Cophignon J; Harris AG Acta Endocrinol (Copenh); 1991 Apr; 124(4):487-91. PubMed ID: 2031445 [TBL] [Abstract][Full Text] [Related]
5. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Gancel A; Vuillermet P; Legrand A; Catus F; Thomas F; Kuhn JM Clin Endocrinol (Oxf); 1994 Mar; 40(3):421-8. PubMed ID: 8187308 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of long-acting octreotide in suppressing hormonogenesis and tumor growth in thyrotropin-secreting pituitary adenomas: report of two cases. Gourgiotis L; Skarulis MC; Brucker-Davis F; Oldfield EH; Sarlis NJ Pituitary; 2001 Aug; 4(3):135-43. PubMed ID: 12138986 [TBL] [Abstract][Full Text] [Related]
7. A human TSH-secreting adenoma: endocrine, biochemical and morphological studies. Evidence of somatostatin receptors by using quantitative autoradiography. Clinical and biological improvement by SMS 201-995 treatment. Polak M; Bertherat J; Li JY; Kujas M; Le Dafniet M; Weizani H; Van Effenterre R; Epelbaum J; Turpin G Acta Endocrinol (Copenh); 1991 Apr; 124(4):479-86. PubMed ID: 1851593 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. Caron P; Arlot S; Bauters C; Chanson P; Kuhn JM; Pugeat M; Marechaud R; Teutsch C; Vidal E; Sassano P J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898 [TBL] [Abstract][Full Text] [Related]
9. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Chanson P; Weintraub BD; Harris AG Ann Intern Med; 1993 Aug; 119(3):236-40. PubMed ID: 8323093 [TBL] [Abstract][Full Text] [Related]
10. Long term treatment with the somatostatin analog SMS 201-995 in a patient with a thyrotropin- and growth hormone-secreting pituitary adenoma. Wémeau JL; Dewailly D; Leroy R; D'Herbomez M; Mazzuca M; Decoulx M; Jaquet P J Clin Endocrinol Metab; 1988 Mar; 66(3):636-9. PubMed ID: 2895119 [TBL] [Abstract][Full Text] [Related]
11. A case of thyrotropin-secreting pituitary microadenoma with normal thyrotropin alpha-subunit level. Ozata M; Oztürk E; Narin Y; Tayfun C; Azal O; Beyhan Z; Corakçi A; Bayhan H; Gündoğan MA Thyroid; 1997 Jun; 7(3):441-7. PubMed ID: 9226217 [TBL] [Abstract][Full Text] [Related]
12. Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide. Orme SM; Lamb JT; Nelson M; Belchetz PE Postgrad Med J; 1991 May; 67(787):466-8. PubMed ID: 1852668 [TBL] [Abstract][Full Text] [Related]
13. Effect of octreotide acetate on thyrotropin-secreting adenoma: report of two cases and review of the literature. Yoenem A; Cakyr B; Azal O; Corakcy A; Kutlu M; Oezata M Endocr Regul; 1999 Dec; 33(4):169-74. PubMed ID: 10700085 [TBL] [Abstract][Full Text] [Related]
14. Treatment of thyrotropin-secreting pituitary adenomas with octreotide. Shimatsu A; Murabe H; Kamoi K; Suzuki Y; Nakao K Endocr J; 1999 Feb; 46(1):113-23. PubMed ID: 10426575 [TBL] [Abstract][Full Text] [Related]
15. The treatment of a thyrotropin-secreting pituitary macroadenoma with octreotide in twin pregnancy. Blackhurst G; Strachan MW; Collie D; Gregor A; Statham PF; Seckl JE Clin Endocrinol (Oxf); 2002 Sep; 57(3):401-4. PubMed ID: 12201834 [TBL] [Abstract][Full Text] [Related]
16. Successful pregnancy in an infertile woman with a thyrotropin-secreting macroadenoma treated with somatostatin analog (octreotide). Caron P; Gerbeau C; Pradayrol L; Simonetta C; Bayard F J Clin Endocrinol Metab; 1996 Mar; 81(3):1164-8. PubMed ID: 8772594 [TBL] [Abstract][Full Text] [Related]
17. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment. Teramoto A; Sanno N; Tahara S; Osamura YR Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102 [TBL] [Abstract][Full Text] [Related]
18. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients. Rimareix F; Grunenwald S; Vezzosi D; Rivière LD; Bennet A; Caron P Thyroid; 2015 Aug; 25(8):877-82. PubMed ID: 26244412 [TBL] [Abstract][Full Text] [Related]
19. An unusual somatotropin and thyreotropin secreting pituitary adenoma efficiently controlled by Octreotide and Pegvisomant. Meas T; Sobngwi E; Vexiau P; Boudou P Ann Endocrinol (Paris); 2006 Jun; 67(3):249-52. PubMed ID: 16840917 [TBL] [Abstract][Full Text] [Related]
20. TSH producing pituitary tumor: biochemical diagnosis and long-term medical management with octreotide. Chayen SD; Gross D; Makhoul O; Glaser B Horm Metab Res; 1992 Jan; 24(1):34-8. PubMed ID: 1612557 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]